Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511365 · ClinicalTrials.gov registry record · Phase 1
Effects of Probiotic on Inflammation and Microbiota in Patients With NASH
A Phase 1 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03511365 is a Phase 1 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 6 participants.
The verdict
NCT03511365, a Phase 1 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination. The probiotic formulation VSL#3 450 Billion CFU twice daily will be administered for 8 weeks and the determination of Il-17 and microbiome will be repeated. Each subject will serve as his or her own control.
Interventions
- BIOLOGICAL Probiotic Formulation VSL#3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2019-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03511365
The ClinicalTrials.gov registry entry for NCT03511365 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Probiotic Formulation VSL#3 is the first listed.
NCT03511365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03511365 about?
NCT03511365 is a clinical study titled "Effects of Probiotic on Inflammation and Microbiota in Patients With NASH". Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination. The probiotic formulation VSL#3 450 Billion CFU twice daily will be administered for 8 weeks and the determination of...
What is the current status of trial NCT03511365?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-05-15. Estimated completion is 2019-10-11.
What interventions are being tested in trial NCT03511365?
The interventions under investigation include: Probiotic Formulation VSL#3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03511365?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.